NCT03070392 2026-03-17
Safety and Efficacy of IMCgp100 Versus Investigator Choice in Advanced Uveal Melanoma
Immunocore Ltd
Phase 2 Completed
Clinical Trials
42 trialsNCT07310784 2026-03-03
A Phase II Trial of LM103 in Advanced Melanoma
Suzhou BlueHorse Therapeutics Co., Ltd.
Phase 2 Recruiting
NCT06346067 2026-02-27
A Study to Assess Naporafenib (ERAS-254) Administered With Trametinib in Patients With NRAS-mutant Melanoma (SEACRAFT-2)
Erasca, Inc.
Phase 3 Active not recruiting
NCT06703398 2025-12-23
MIZAR-003
Shanghai Juncell Therapeutics
Phase 2 Recruiting
NCT00600496 2025-11-13
A Phase I, Open-Label, Multi-center Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD6244 (ARRY-142886)
AstraZeneca
Phase 1 Active not recruiting
NCT06624644 2025-09-10
A Trial of LNS8801 With or Without Pembrolizumab in Patients With Refractory Melanoma
Linnaeus Therapeutics, Inc.
Phase 2/3 Recruiting
NCT00087776 2025-07-23
Study of Taxoprexin Injection vs. Dacarbazine in Patients With Metastatic Malignant Melanoma
American Regent, Inc.
Phase 3 Terminated
NCT01721772 2022-07-12
CheckMate 066
Bristol-Myers Squibb
Phase 3 Completed
NCT01721746 2022-04-19
A Study to Compare BMS-936558 to the Physician's Choice of Either Dacarbazine or Carboplatin and Paclitaxel in Advanced Melanoma Patients That Have Progressed Following Anti-CTLA-4 Therapy (CheckMate 037)
Bristol-Myers Squibb
Phase 3 Completed
NCT02076646 2022-04-14
A Phase I/II Dose Escalation Study of the Tumor-targeting Human L19-IL2 Monoclonal Antibody-cytokine Fusion Protein in Combination With Dacarbazine for Patients With Metastatic Melanoma
Philogen S.p.A.
Phase 1/2 Unknown
NCT02288897 2022-01-19
PV-10 vs Chemotherapy or Oncolytic Viral Therapy for Treatment of Locally Advanced Cutaneous Melanoma
Provectus Pharmaceuticals
Phase 3 Terminated
NCT01763164 2021-03-22
Study Comparing the Efficacy of MEK162 Versus Dacarbazine in Unresectable or Metastatic NRAS Mutation-positive Melanoma
Pfizer
Phase 3 Completed
NCT01280565 2020-11-05
Masitinib in Non-Resectable or Metastatic Stage 3/4 Melanoma Carrying a Mutation in the Juxta Membrane Domain of c-Kit
AB Science
Phase 3 Terminated
NCT02545075 2020-05-19
A Comparative Study in Chinese Subjects With Chemotherapy Naïve Stage IV Melanoma Receiving Ipilimumab (3 mg/kg) vs. Dacarbazine
Bristol-Myers Squibb
Phase 3 Completed
NCT01704287 2020-05-18
KEYNOTE 002
Merck Sharp & Dohme LLC
Phase 2 Completed
NCT04200040 2020-02-27
A Clinical Study to Evaluate the Safety and Efficacy of OrienX010 in Unresectable Malignant Melanoma Patients
OrienGene Biotechnology Ltd.
Phase 2 Unknown
NCT00864253 2019-10-30
A Trial of ABI-007 Versus Dacarbazine in Previously Untreated Patients With Metastatic Malignant Melanoma
Celgene
Phase 3 Completed
NCT01693068 2018-01-05
Phase II Trial of Pimasertib Versus Dacarbazine in N-Ras Mutated Cutaneous Melanoma
EMD Serono
Phase 2 Completed
NCT01227889 2017-10-04
A Study Comparing GSK2118436 to Dacarbazine (DTIC) in Previously Untreated Subjects With BRAF Mutation Positive Advanced (Stage III) or Metastatic (Stage IV) Melanoma
GlaxoSmithKline
Phase 3 Completed
NCT00849875 2017-07-12
A Study of Safety and Clinical Activity of Immunotherapy Plus Chemotherapy in Metastatic Melanoma Patients
GlaxoSmithKline
Phase 2 Terminated
NCT00091572 2017-06-06
Temozolomide Versus Dacarbazine in Stage IV Metastatic Melanoma (Study P03267)
Merck Sharp & Dohme LLC
Phase 3 Completed
NCT01133977 2016-10-10
E7080 (Lenvatinib) in Combination With Dacarbazine Versus Dacarbazine Alone as First Line Therapy in Patients With Stage IV Melanoma
Eisai Inc.
Phase 1/2 Completed
NCT01006980 2016-09-28
A Study of Vemurafenib (RO5185426) in Comparison With Dacarbazine in Previously Untreated Patients With Metastatic Melanoma (BRIM 3)
Hoffmann-La Roche
Phase 3 Completed
NCT00936221 2016-03-14
Comparison of AZD6244 in Combination With Dacarbazine Versus (vs) Dacarbazine Alone in BRAF Mutation Positive Melanoma Patients
AstraZeneca
Phase 2 Completed
NCT01028222 2015-12-30
TEAM
Novartis
Phase 2 Completed
NCT01681212 2015-06-11
Phase 2 Study of Ipilimumab Plus Dacarbazine in Japanese Patients With Advanced Melanoma
Bristol-Myers Squibb
Phase 2 Completed
NCT00110994 2015-06-08
Treatment for Subjects With Unresectable Stage III or Stage IV Melanoma
Bayer
Phase 2 Completed
NCT00492297 2014-10-31
A Phase II, Multi-Center, Open-Label, Uncontrolled Study to Evaluate the Efficacy and Safety of Sorafenib Given Daily in Combination With Repeated 21-Day Cycles of Dacarbazine (DTIC) Chemotherapy in Subjects With Advanced Metastatic Melanoma
Bayer
Phase 2 Completed
NCT00533702 2014-08-01
A Study of IMC-1121B (Ramucirumab) With or Without Dacarbazine in Metastatic Malignant Melanoma
Eli Lilly and Company
Phase 2 Completed
NCT01055522 2014-02-25
Clinical Study Phase II of L19IL2 in Combination With Dacarbazine in Patients With Metastatic Melanoma
Philogen S.p.A.
Phase 2 Terminated
NCT00395070 2013-09-13
A Phase 3 Pivotal Trial Comparing Allovectin-7® Alone vs Chemotherapy Alone in Patients With Stage 3 or Stage 4 Melanoma
Vical
Phase 3 Completed
NCT00246012 2013-08-19
A Safety and Efficacy Study of Intetumumab, Alone and in Combination With Dacarbazine, in Participants With Stage 4 Melanoma
Centocor, Inc.
Phase 1/2 Completed
NCT00257205 2012-07-02
CP-675,206 Versus Either Dacarbazine Or Temozolomide In Patients Without Prior Therapy
AstraZeneca
Phase 3 Completed
NCT00518895 2011-11-07
AGENDA
Genta Incorporated
Phase 3 Completed
NCT00327600 2010-09-15
Safety and Efficacy Trial of Imexon Plus DTIC in Advanced Malignant Melanoma
AmpliMed Corporation
Phase 1/2 Completed
NCT00991250 2010-02-05
SentoClone® Compared to Reference Treatment in Advanced Malignant Melanoma
SentoClone AB
Phase 2 Unknown
NCT00911443 2009-07-09
Thymosin Alpha 1, Interferon Alpha, or Both, in Combination With Dacarbazine in Patients With Malignant Melanoma
sigma-tau i.f.r. S.p.A.
Phase 2 Completed
NCT00516802 2009-05-15
A Study to Assess the Safety and Pharmacokinetics of an Inhibitor of PARP in Combination With Dacarbazine
AstraZeneca
Phase 1 Completed
NCT00070642 2009-02-10
CPG 7909 Injection in Melanoma
Pfizer
Phase 2 Completed
NCT00099970 2008-08-05
Volociximab in Combination With DTIC in Patients With Metastatic Melanoma Not Previously Treated With Chemotherapy
Facet Biotech
Phase 2 Completed
NCT00003647 2008-07-25
Chemotherapy With or Without Immunotherapy in Treating Patients With Stage III or Stage IV Melanoma
Vical
Phase 3 Completed
NCT00066196 2008-01-15
Evaluating The Antitumor Activity Of MEDI-522 With Or Without Dacarbazine In Patients With Metastatic Melanoma
MedImmune LLC
Phase 2 Completed